TAKEDA PHARMACEUTICAL CO LTDTAK

時価総額

PER

医薬品開発・製造の最大手。希少疾患や血漿由来治療薬、バイオ製剤の研究開発と製造を展開。2023年2月にNDI-034858の権利を40億USDで買収。大阪新工場へ950億円投資を発表（2025年度着工、2029年度完成予定）、米国ロサンゼルスへ346億円投資、ケンブリッジで2817億円のR&D拠点建設中。日本・米国・欧州中心に展開。

概要財務

サマリーテーブルに戻る

	2019年 3月31日	2020年 3月31日	2021年 3月31日	2022年 3月31日	2023年 3月31日	2024年 3月31日
Profit (loss)	109,014	44,290	376,171	230,166	317,038	144,197
Depreciation and amortization	272,446	583,649	559,671	583,151	664,400	728,002
Impairment loss	10,120	101,882	25,452	54,515	64,394	150,017
Equity-settled share-based compensation	20,084	29,122	37,663	43,374	60,672	70,871
Loss on sales and disposal of property, plant and equipment	45,220	990	2,109	-655	-10	-6,052
Gain on divestment of business and subsidiaries	-	-	-	7,829	6,807	7,832
Increase (decrease) in contingent consideration asset (liability)	-5,966	-18,387	59,277	-11,195	3,991	20,757
Finance (income) and expenses, net	-	-137,175	-143,110	-142,907	-106,785	-167,757
Share of loss (profit) of investments accounted for using the equity method	-	-	-	-	-	6,473
Income tax expenses (benefit)	-14,118	-105,044	-9,936	72,405	58,052	-91,406
Decrease in trade and other receivables	-13,382	-34,826	-9,316	127,294	75,127	15,104
Increase in inventories	58,678	137,492	25,978	-46,148	-79,155	-115,743
Increase (decrease) in trade and other payables	-16,413	-29,932	36,620	125,157	-84,804	-9,895
Increase (decrease) in provisions	-47,063	-21,938	-49,099	58,090	-31,899	126,901
Increase (decrease) in other financial liabilities	-	-	173,400	-49,608	31,669	-18,568
Other, net	-73,347	22,520	37,786	41,409	-88,778	-7,556
Cash generated from operations	373,388	896,520	1,212,618	1,263,528	1,163,122	918,383
Income taxes paid	51,536	234,612	235,801	147,724	198,439	219,941
Tax refunds and interest on tax refunds received	6,627	7,844	34,114	7,301	12,473	17,902
Net cash from operating activities	328,479	669,752	1,010,931	1,123,105	977,156	716,344
Interest received	6,305	11,487	1,105	2,919	5,054	11,161
Dividends received	2,739	1,382	387	3,401	3,562	13,191
Acquisition of property, plant and equipment	77,677	127,082	111,206	123,252	140,657	175,420
Proceeds from sales of property, plant and equipment	50,717	12,578	46,453	1,815	962	8,606
Acquisition of intangible assets	56,437	90,628	125,262	62,785	493,032	305,310
Acquisition of investments	17,099	7,551	12,596	8,341	10,151	6,766
Proceeds From Sale Of Investments	65,035	49,402	74,604	16,921	22,254	8,021
Acquisition of businesses, net of cash and cash equivalents acquired	2,958,686	4,890	-	49,672	-	-
Proceeds from sales of business, net of cash and cash equivalents divested	85,131	461,546	530,388	28,196	7,958	19,959
Payments for the settlement of forward exchange contracts designated as net investment hedges	-	-	-	-	-	33,300
Other, net	-7,570	-14,125	-10,343	-7,328	-3,052	-4,003
Net cash used in investing activities	-2,835,698	292,119	393,530	-198,125	-607,102	-463,862
Proceeds From (Payments For) Short-Term Borrowings	367,319	-351,223	-149,043	-2	40,000	277,000
Proceeds from issuance of bonds and long-term loans	2,795,926	496,190	1,179,515	249,334	75,000	100,000
Repayments of bonds and long-term loans	-	701,057	1,651,706	810,115	356,670	320,901
Proceeds From The Settlement Of Swaps	-	-	-	-	-	60,063
Acquisition of treasury shares	1,172	3,737	2,141	77,531	26,929	2,326
Interest paid	34,914	127,211	107,350	108,207	108,555	100,375
Dividends paid	142,952	282,582	283,357	283,665	279,416	287,188
Repayments of lease liabilities	-	30,000	39,270	39,694	43,401	54,586
Other, net	-14,330	-3,893	-172	-385	-9,178	-26,102
Net cash used in financing activities	2,946,237	-1,005,213	-1,088,354	-1,070,265	-709,148	-354,416
Net decrease in cash and cash equivalents	439,018	-43,342	316,107	-145,285	-339,094	-101,934
Effect of exchange rate changes on cash and cash equivalents	31,269	21,766	12,501	28,758	22,929	26,204